{"id":15952,"date":"2025-08-22T10:31:07","date_gmt":"2025-08-22T10:31:07","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/15952\/"},"modified":"2025-08-22T10:31:07","modified_gmt":"2025-08-22T10:31:07","slug":"glp-1s-cut-cv-risks-tied-to-type-2-diabetes-and-ad","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/15952\/","title":{"rendered":"GLP-1s Cut CV Risks Tied to Type 2 Diabetes and AD"},"content":{"rendered":"<p><strong>TOPLINE:<\/strong><\/p>\n<p>GLP-1 receptor agonists (RAs) cut cardiovascular risks among patients with type 2 diabetes (T2D) and atopic dermatitis (AD) in this analysis.<\/p>\n<p><strong>METHODOLOGY:<\/strong><\/p>\n<ul>\n<li>Analysis included 17,099 propensity score-matched patient pairs with T2D, with or without AD (mean age, 53 years; 67% women), in the TriNetX Linked network between 2015 and 2025, including pairs treated with GLP-1 RAs.<\/li>\n<li>About 36% of patients were White, 24% were Black, 5% were Asian, and 9% were Hispanic or Latino individuals.<\/li>\n<li>Primary outcomes included all-cause mortality, new-onset major adverse cardiovascular events (MACE), myocardial infarction (MI), heart failure, and ischemic stroke within 10 years.<\/li>\n<\/ul>\n<p><strong>TAKEAWAY:<\/strong><\/p>\n<ul>\n<li>Patients with AD vs those without AD showed higher risks for MI (hazard ratio [HR], 1.17; P = .001), heart failure (HR, 1.36; P = .001), and ischemic stroke (HR, 1.32; P = .001), but not for MACE.<\/li>\n<li>Patients with AD had a significantly lower risk for mortality (HR, 0.67; P\u00a0= .001) than those without AD.<\/li>\n<li>Among T2D patients with or without AD who were treated with GLP-1 RAs, no differences were seen in the risks for mortality, new-onset MACE, MI, heart failure, or stroke.<\/li>\n<li>Interaction analyses showed that GLP-1 RAs significantly reduced the risk for new-onset MACE (P = .043), MI (P = .015), heart failure (P = .007), and ischemic stroke (P = .003) in patients with AD and T2D.<\/li>\n<\/ul>\n<p><strong>IN PRACTICE:<\/strong><\/p>\n<p>\u201cAmong patients with T2D and AD, GLP-1 RAs significantly mitigated the risk of new-onset MACE, myocardial infarction, heart failure, and ischemic stroke compared to T2D controls without AD, suggesting that GLP-1 RAs may be effective options for reducing cardiovascular disease in this population,\u201d the study authors wrote.<\/p>\n<p><strong>SOURCE:<\/strong><\/p>\n<p>The study was co-led by Natalie Braun, BA; Claire Lin, BA; Steven T. Chen, MD, MPH, MS-HPEd; and Kevin Sheng-Kai Ma, DDS, FRSPH, FRSM, Department of Dermatology, Massachusetts General Hospital, Boston. It was <a href=\"https:\/\/www.jaad.org\/article\/S0190-9622(25)02645-3\/fulltext\" rel=\"nofollow noopener\" target=\"_blank\">published online<\/a> on August 18 in the Journal of the American Academy of Dermatology.<\/p>\n<p><strong>LIMITATIONS:<\/strong><\/p>\n<p>Limitations included the study\u2019s retrospective design, reliance on billing codes, inability to control for GLP-1 RA treatment duration, and the shorter follow-up time in the GLP-1 RA-treated subgroups.<\/p>\n<p><strong>DISCLOSURES:<\/strong><\/p>\n<p>This study did not receive any funding, and the authors declared having no conflicts of interest.<\/p>\n<p>This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.<\/p>\n","protected":false},"excerpt":{"rendered":"TOPLINE: GLP-1 receptor agonists (RAs) cut cardiovascular risks among patients with type 2 diabetes (T2D) and atopic dermatitis&hellip;\n","protected":false},"author":2,"featured_media":15953,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[14431,14430,18,4009,4010,135,137,14433,19,17,14432,14429],"class_list":{"0":"post-15952","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-atopic-dermatitis-atopic-eczema","9":"tag-dermatitis","10":"tag-eire","11":"tag-glp-1-receptor-agonists","12":"tag-glucagon-like-peptide-1-receptor-agonists","13":"tag-health","14":"tag-heart","15":"tag-heart-failure-heart-failure-hf","16":"tag-ie","17":"tag-ireland","18":"tag-stroke-cerebrovascular-accident-cva-cerebrovascular-accident-cva","19":"tag-type-2-diabetes-mellitus-diabetes-mellitus-type-2-diabetes-mellitus-type-ii-type-2-diabetes-type-2-dm-t2dm-t2d-type-2-diabetes-mellitus-t2dm-type-2-diabetes-t2d"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/15952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=15952"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/15952\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/15953"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=15952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=15952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=15952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}